To correct an error in the original article regarding the role of sirtuins in autoimmune diseases.
Approach:
Correction Details: The term 'gramoxone acetate' was incorrectly used in the context of multiple sclerosis. The correction specifies that PBMCs were collected from patients treated with glatiramer acetate.
Key Findings:
The term 'gramoxone acetate' was mistakenly used in the original article regarding multiple sclerosis.
The correction specifies that PBMCs were collected from patients treated with glatiramer acetate.
Interpretation:
The correction addresses the error in treatment context in the study of sirtuins in multiple sclerosis.
Conclusion:
The original article has been updated to reflect this correction.
